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Paget disease of bone (PDB) is a common disorder characterized by focal and disorganized increases of bone
turnover. Genetic factors are important in the pathogenesis of PDB. We and others recently mapped the third locus
associated with the disorder, PDB3, at 5q35-qter. In the present study, by use of 24 French Canadian families and
112 unrelated subjects with PDB, the PDB3 locus was confined to ∼300 kb. Within this interval, two disease-
related haplotype signatures were observed in 11 families and 18 unrelated patients. This region encoded the
ubiquitin-binding protein sequestosome 1 (SQSTM1/p62), which is a candidate gene for PDB because of its as-
sociation with the NF-kB pathway. Screening SQSTM1/p62 for mutations led to the identification of a recurrent
nonconservative change (P392L) flanking the ubiquitin-associated domain (UBA) (position 394–440) of the protein
that was not present in 291 control individuals. Our data demonstrate that two independent mutational events at
the same position in SQSTM1/p62 caused PDB in a high proportion of French Canadian patients.
Paget disease of bone (PDB [MIM 167250]) is a chronic
disease of the skeleton that affects up to 2%–3% of the
population aged 140 years (Siris and Canfield 1990;
Klein and Norman 1995). The disorder is characterized
by focal areas of increased and disorganized bone turn-
over, leading to bone pain, deformity, pathological frac-
ture, neurological complications, and an increased risk
of osteosarcoma (Hamdy 1995; Kanis 1998).
Genetic factors play an important role in the patho-
genesis of PDB. The disease often segregates as an au-
tosomal dominant trait manifesting genetic heterogeneity
and incomplete penetrance (Haslam et al. 1998; Nance
et al. 2000; Good et al. 2001; Hocking et al. 2001; Laurin
et al. 2001; Leach et al. 2001). The disorder was initially
linked to susceptibility loci at chromosomes 6p21.3
(PDB1) and 18q21-22 (PDB2) (Fotino et al. 1977; Til-
yard et al. 1982; Cody et al. 1997; Haslam et al. 1998).
PDB2 also contains the gene responsible for familial ex-
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pansile osteolysis (FEO [MIM174810]) (Hughes et al.
1994), a rare bone dysplasia with some similarities to
PDB. However, the involvement of PDB1 and PDB2may
be restricted to only a few families, since linkage analyses
excluded these two loci in the vast majority of the pagetic
kindreds subsequently studied (Breanndan Moore and
Hoffman 1988; Hocking et al. 2000; Nance et al. 2000;
Good et al. 2001; Laurin et al. 2001).
The primary cellular defect of PDB seems to reside in
the osteoclasts. Within the pagetic lesion, osteoclasts are
large, multinucleated, and overactive and contain par-
amyxovirus-like inclusions (Rebel et al. 1974; Mills and
Singer 1976; Howatson and Fornasier 1982). Osteoclast
formation and activation involve the receptor activator
of NF-kB (RANK) pathway, a tumor-necrosis factor
(TNF) family member (Hsu et al. 1999). Activating mu-
tations of the TNFRSF11A gene encoding this receptor
have been found to be responsible for FEO and rare
cases of early-onset familial PDB (Hughes et al. 2000).
Targeted disruption of several components of this sig-
naling pathway in the mouse, including RANK, RANK
ligand, TRAF6, and NF-kB1/NF-kB2, affects osteoclast
differentiation and/or activity leading to osteopetrosis
(reviewed by McLean and Olsen [2001]).
Exploiting a genomewide-scan approach and large
French Canadian families, we recently mapped two new
Reports 1583
Figure 1 Haplotype analysis in French Canadian families with PDB (common, DD, PT, CT, and GE families) and allele combinations of
informative sporadic cases (UN096, UN054, UN070, and UN010). Markers are indicated on the left, with the 1215CrT mutation and two
informative SNPs at position 916 and 976 in the coding region of SQSTM1/p62. The marker order is based on haplotype analysis of 24 families
(379 individuals), allowing the lower level of recombination. Shared haplotypes are represented by vertical black bars (PDB3H1) or are boxed
(PDB3H2). Because haplotypes of sporadic cases could not be determined, both alleles for heterozygotic markers are depicted.
PDB-causing genes, at 5q35-qter (PDB3) and 5q31
(PDB4) (Laurin et al. 2001). Using a different set of fam-
ilies, Hocking et al. also described a candidate locus at
chromosome 5q35 (Hocking et al. 2001). We report here
the confinement of the PDB3 locus to ∼300 kb and the
identification of a recurrent mutation in SQSTM1/p62, a
gene also involved in the NF-kB signaling pathway.
Blood samples were obtained from 479 family mem-
bers, 112 sporadic patients, and 205 individuals from
the general population (108 men and 97 women, mean
age 62 years, residing within a 50-km radius of Quebec
City, contacted at random, and almost all French Ca-
nadian). All affected individuals displayed the typical
phenotype for adult-onset PDB, with characteristic ra-
diographic and scintigraphic abnormalities. A detailed
clinical description of the families and clinical proce-
dures has been presented elsewhere (Laurin et al. 2001).
A full set of pedigree drawings for families included in
the present study is also available at the CHUL Research
Center Web site.
We previously reported that one founder disease hap-
lotype cosegregated with Paget disease in eight families
showing linkage at PDB3. One ancestral recombination
event in one of these families restricted the disease interval
to within 6 cM. To further refine this interval, we devel-
oped eight new microsatellite markers, using the Human
Genome Working Draft sequence, and performed satu-
ration mapping. We searched for (CA)n and (TG)n repeats
on sequences of BAC clones included within the contig
covering the 6-cM interval. Flanking primers were de-
signed by use of Primer 3 software (Primer 3 Software
Distribution Web site). The more-informative markers
were retained. The sequences of these primers are avail-
able at the CHUL Research Center Web site. Purified PCR
products were pooled and genotyped on a 377 ABI se-
quencer. Data were analyzed with GENOTYPER 2.5
(ABI). Haplotypes were constructed by use of SIMWALK
2.8 (Sobel and Lange 1996). This analysis strengthened
the inference of a common founder haplotype in the eight
families originally linked at PDB3. This haplotype was
named PDB3H1 (fig. 1, alleles within black vertical bars).
These new markers allowed us, by means of the DD fam-
ily, to position the disease interval between NL5 and the
telomere (fig. 1).
We then exploited a haplotype signature strategy to
find ancestral haplotypes shared by affected individuals.
The French Canadian population, which frequently
shows founder effects, is particularly well suited for such
a procedure (Scriver 2001). Genotyping of 112 unrelated
patients revealed that 8 of them harbored part of the
PDB3H1 haplotype for several contiguous markers. A
second signature was also detected in 10 patients with
sporadic PDB, and its counterpart haplotype was ob-
served in 10 affected members of three additional kin-
dreds. This haplotype was named “PDB3H2” (fig. 1,
boxed alleles). In one of these three families, three of
eight patients did not share any of the disease-related
haplotypes, suggesting the presence either of a second
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disease gene, located at a different PDB locus, or of
nongenetic (environmental) phenocopies (see pedigree
CT at the CHUL Research Center Web site). As is de-
picted in figure 1, four patients with sporadic PDB who
carried short portions of either of the two haplotype
signatures and the pedigree GE haplotype allowed us to
confine the PDB3 locus within an interval of ∼300 kb,
between markers NL5 and NL25.
We searched the Unigene and the LocusLink data-
bases, from the National Center for Biotechnology In-
formation (NCBI) server, for genes and ESTs mapping
within the PDB3 locus. Particular interest was put on
those genes mapping within the reduced interval (fig.
2A, B, and C). Two of these were sequestosome 1
(SQSTM1/p62), which mediates intracellular signaling
through the IL-1/TNF pathways towards NF-kB (Sanz
et al. 1999, 2000) and MAPK9, a potential component
of the RANK signaling pathway. On the basis of the
association between these pathways and osteoclast dif-
ferentiation/activation, we thoroughly screened these
two genes for mutations. We did not find any sequence
variation within the MAPK9 gene.
The 2,870-nt SQSTM1/p62 transcript is contained
within eight exons distributed over a 16-kb genomic
segment (fig. 2D). Exon 1 encodes the methionine start
codon at position 41, whereas exon 8 encompasses the
stop codon at position 1363 and the entire 3′ UTR (fig.
2D and 2E). We initially tested five affected members
of the DD and TH families, who carried the PDB3H1
haplotype, as well as two unaffected individuals 154
years old that we investigated. One of these five symp-
tomatic individuals, TH-143, was homozygous for
PDB3H1 (Laurin et al. 2001). This homozygote was a
member of a severely affected nucleus, and his phenotype
was similar to that of his heterozygotic sibs. We designed
primer pairs for amplification of the eight coding exons
of SQSTM1/p62 and at least 30 nt of each of the neigh-
boring intronic sequences. Amplification products were
purified and sequenced on a 3700 ABI sequencer using
the Big Dye Deoxy Terminator Cycle Sequencing kit
(ABI). Both strands were analyzed using STADEN pack-
age 1.1 (Staden 1996).
This screening revealed a CrT transversion at position
1215 in SQSTM1/p62 exon 8 in all five affected indi-
viduals (fig. 3). This change caused the substitution of
proline 392 to a leucine (P392L). Sequencing of exon 8
in the eight families sharing the PDB3H1 disease hap-
lotype demonstrated that the P392L variant was present
in all affected individuals carrying the disease haplotype
and therefore cosegregated with PDB. Genomic sequence
analysis of exon 8 in 86 nonaffected spouses and 205
individuals from the general population revealed no se-
quence variations at this position, indicating that this
sequence change was unlikely to be a single-nucleotide
polymorphism.
To further test this association between SQSTM1/p62
and PDB, we screened for mutations among 112 spo-
radic cases and the remaining 16 families. The same
1215CrT substitution was detected in 10 affected in-
dividuals from three additional families and in 18 pa-
tients with sporadic PDB, all of them harboring one of
the two haplotypic signatures described above. The
SQSTM1/p62P392L mutation was thus found in 18 (16%)
of the 112 sporadic cases and in 11 (46%) of the 24
families tested. We did not find additional disease-caus-
ing mutations. We did, however, identify five SNPs:
380CrT (A117V), in exon 3; 862GrC (Q274E), in
exon 6; 916CrT (E292E), in exon 6; 976GrA (R312R),
in exon 6; and 994CrA (S318S), in exon 6. Frequencies
of these five SNPs were similar between affected and
unaffected subjects. None of these SNPs had alleles as-
sociated with the mutation. However, as is depicted in
fig. 1, two of these SNPs, 916CrT and 928GrA,
showed distinct alleles cosegregating with the PDB3H1
and PDB3H2 disease haplotypes. These two SNPs were
therefore used as proximal markers to further dissociate
the two disease haplotypes. For instance, the PDB3H1
haplotype harbored a T and an A at positions 916 and
976, respectively, whereas the PDB3H2 signature dis-
played a C and a G at these two positions.
The 1215CrT transversion in exon 8 resulted in the
substitution of a cyclic amino acid proline residue at
position 392 for a leucine. This residue was conserved
in the mouse and rat homologues, Osi (oxydative stress
induced) (GenBank accession number NM_011018) and
Zip (PKC-zeta-interacting protein) (GenBank accession
number Y08355), respectively. The P392 residue being
located within the C-terminal end of the protein flanking
the ubiquitin associated domain (UBA) (Hofmann and
Bucher 1996; Schultz et al. 1998; Wilkinson et al. 2001)
at position 394–440 could thus be of particular impor-
tance for the conformation and/or function of this
region.
Cosegregation of the P392L variant with the pheno-
type, its absence in 86 spouses and 205 individuals from
the general population, the nonconservative nature of
the amino acid substitution, and the conservation of the
UBA domain, including the P392 residue, among other
species (mouse and rat) provided support for the idea
that this amino acid change was causing PDB. Except
for homozygote TH-143 (fig. 3), pagetic individuals car-
rying the P392L variant were all heterozygotes, confirm-
ing the dominant mode of action of this mutation in a
high proportion of our French Canadian patients. As 13
of the 24 families investigated did not harbor any mu-
tation in the SQSTM1/p62 coding sequence, it is likely
that other disease gene(s) are also associated with PDB,
in agreement with the well-established genetic hetero-
geneity of the disorder (Haslam et al. 1998; Hocking et
al. 2001; Laurin et al. 2001; Good et al. 2002). Indeed,
Figure 2 Physical map of the PDB3 locus at 5q35-qter and genomic organization of SQSTM1/p62. We retrieved a contig of candidate
BACs, overlapping the PDB interval from the Human Genome Project Working Draft (Golden Path). We localized Ge´ne´thon microsatellite
markers (Dib et al. 1996), present within this interval, using an ePCR approach (Schuler 1998). Genotyping additional markers using the same
approach confirmed order of the BAC clones. A, Chromosome 5. B, BAC contig of the PDB3 linkage region and localization of microsatellite
markers. Eight new markers were developed for this study; NL5 and NL25 defined the 300-kb PDB critical interval. The asterisk (*) indicates
the NL7–NL5 subcontig being in a different order relative to the Golden Path (August 2001 release). C, Genes present within the PDB3 linkage
region. D, Genomic structure of SQSTM1/p62. Exons are represented as boxes and intronic sequences as thin bars. E, cDNA and mutation
localization. The segments encoding the Phox and Bem1p domain (PB1), zinc finger ZZ, and UBA domains (Schultz et al. 1998; SMART Web
site) are shown by black boxes.
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Figure 3 SQSTM1/p62 mutation P392L. Sequence electrophor-
egram of a wild-type unaffected subject (top panel) and heterozygous
or homozygous patients (middle and lower panels). Nucleotide and
predicted amino acid changes are indicated on the left. The arrows
point to the mutation. The nucleotide sequences of primers annealing
to exon 8–flanking intronic DNA used for amplification and sequenc-
ing of exon 8 were as follows: forward, 5′-CACTGTGGCCTGTGAG-
GAC-3′, and reverse, 5′-CAGTGAGCCTTGGGTCTCG-3′. A full de-
scription of the primers used for amplification and sequencing is
available at the CHUL Research Center Web site.
we recently mapped 2 of these 13 families to a fourth
locus for the disorder, PDB4, at 5q31 (Laurin et al.
2001), and there is evidence for three other loci asso-
ciated with the disorder: PDB5 at 2q36, PDB6 at 10p13,
and a locus at 18q23 (Hocking et al. 2001; Good et al.
2002).
Haplotype analysis by means of intragenic SNPs was
useful in determination of the origin of the mutation and
the genetic relatedness of the patients carrying it. Indeed,
we found that the P392L mutation, associated with two
distinct haplotypes, probably originated from two in-
dependent events. Since two different intragenic SNPs
haplotypes were identified, our data do not support a
very ancient common founder for this mutation. This
mutation, occurring at a hypermutable CpG dinucleo-
tide sequence (Green et al. 1990; Koeberl et al. 1990),
might have arisen by deamination of a methylated cy-
tosine. For other disorders, several authors already sug-
gested that such mutational hotspots may explain re-
current mutations (Glaser et al. 1999; Rizzo et al. 1999;
Aksentijevich et al. 2001; Lund et al. 2001). Additional
mutational events may also be found in SQSTM1/p62,
since one other study showed linkage between pagetic
families of different ethnic origins and markers at PDB3
(Hocking et al. 2001).
It has been proposed that SQSTM1/p62 selectively
interacts with TRAF6 and is thus an important inter-
mediary in interleukin-1 (IL-1) and TNFa signaling to-
ward NF-kB activation (Sanz et al. 1999, 2000). TRAF6
interacts with RANK, a member of the TNF receptor
family. Its binding is essential for RANK-induced NF-
kB activation (Darnay et al. 1999), and TRAF6-deficient
mice exhibit severe osteopetrosis and are defective in
osteoclast formation because of impaired signaling in-
duced by RANK (Naito et al. 1999). The functional
importance of SQSTM1/p62 in NF-kB activation has
been further highlighted by the observation that its de-
pletion severely abrogated NF-kB activation through the
TNFa or IL-1 pathways (Sanz et al. 1999, 2000). The
precise role of SQSTM1/p62 remains to be elucidated,
but our data suggest that SQSTM1/p62 may be involved
in signaling pathways that control osteoclast activity,
differentiation or survival. Further studies in both trans-
genic animals and cell-culture systems are required to
understand the cell biology of this disease and the effect
of the SQSTM1/p62P392L mutation.
The present study emphasized the importance of he-
redity in the pathogenesis of adult-onset PDB. Indeed,
the SQSTM1/p62P392L mutation was causing, respec-
tively, 16% and 46% of sporadic and familial cases of
the disorder in the population tested. As two distinct
disease-related haplotypes, encompassing two intragenic
SNPs, shared the same SQSTM1/p62P392L mutation gen-
erated by two independent events, our data suggest that
this recurrent variation may be frequently associated
with PDB in other white populations.
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